APGE
Price
$62.97
Change
-$0.13 (-0.21%)
Updated
Nov 13, 04:59 PM (EDT)
Capitalization
4.3B
Intraday BUY SELL Signals
NUVL
Price
$94.68
Change
-$2.35 (-2.42%)
Updated
Nov 13 closing price
Capitalization
6.88B
110 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

APGE vs NUVL

Header iconAPGE vs NUVL Comparison
Open Charts APGE vs NUVLBanner chart's image
Apogee Therapeutics
Price$62.97
Change-$0.13 (-0.21%)
Volume$94.09K
Capitalization4.3B
Nuvalent
Price$94.68
Change-$2.35 (-2.42%)
Volume$323.37K
Capitalization6.88B
APGE vs NUVL Comparison Chart in %
APGE
Daily Signal:
Gain/Loss:
NUVL
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
APGE vs. NUVL commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APGE is a StrongBuy and NUVL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (APGE: $63.10 vs. NUVL: $97.03)
Brand notoriety: APGE and NUVL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: APGE: 93% vs. NUVL: 61%
Market capitalization -- APGE: $4.3B vs. NUVL: $6.88B
APGE [@Biotechnology] is valued at $4.3B. NUVL’s [@Biotechnology] market capitalization is $6.88B. The market cap for tickers in the [@Biotechnology] industry ranges from $110.25B to $0. The average market capitalization across the [@Biotechnology] industry is $2.1B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APGE’s FA Score shows that 0 FA rating(s) are green whileNUVL’s FA Score has 0 green FA rating(s).

  • APGE’s FA Score: 0 green, 5 red.
  • NUVL’s FA Score: 0 green, 5 red.
According to our system of comparison, both APGE and NUVL are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

APGE’s TA Score shows that 4 TA indicator(s) are bullish while NUVL’s TA Score has 3 bullish TA indicator(s).

  • APGE’s TA Score: 4 bullish, 4 bearish.
  • NUVL’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, APGE is a better buy in the short-term than NUVL.

Price Growth

APGE (@Biotechnology) experienced а +13.80% price change this week, while NUVL (@Biotechnology) price change was +5.36% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.51%. For the same industry, the average monthly price growth was -3.12%, and the average quarterly price growth was +61.90%.

Reported Earning Dates

NUVL is expected to report earnings on Mar 04, 2026.

Industries' Descriptions

@Biotechnology (+1.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NUVL($6.88B) has a higher market cap than APGE($4.3B). APGE YTD gains are higher at: 39.294 vs. NUVL (23.952). APGE has higher annual earnings (EBITDA): -270.1M vs. NUVL (-362.01M). NUVL has more cash in the bank: 1.01B vs. APGE (505M). APGE (0) and NUVL (0) have equivalent revenues.
APGENUVLAPGE / NUVL
Capitalization4.3B6.88B63%
EBITDA-270.1M-362.01M75%
Gain YTD39.29423.952164%
P/E RatioN/AN/A-
Revenue00-
Total Cash505M1.01B50%
Total Debt10.8MN/A-
TECHNICAL ANALYSIS
Technical Analysis
APGENUVL
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
82%
Momentum
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
82%
MACD
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
83%
Declines
ODDS (%)
Bearish Trend 7 days ago
70%
Bearish Trend 4 days ago
78%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
80%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
APGE
Daily Signal:
Gain/Loss:
NUVL
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SGIFX41.480.30
+0.73%
Steward Global Equity Income Fund C
FEEFX96.370.23
+0.24%
American Funds Fundamental Invs 529-F-3
WFALX22.630.02
+0.09%
Allspring Index Asset Allocation C
SPECX36.89-0.34
-0.91%
Alger Spectra A
RPFRX39.83-0.39
-0.97%
Davis Real Estate A

APGE and

Correlation & Price change

A.I.dvisor indicates that over the last year, APGE has been loosely correlated with SYRE. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if APGE jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APGE
1D Price
Change %
APGE100%
+0.24%
SYRE - APGE
59%
Loosely correlated
+0.34%
NUVL - APGE
51%
Loosely correlated
+0.91%
IRON - APGE
51%
Loosely correlated
-0.06%
CLDX - APGE
50%
Loosely correlated
-0.49%
ELVN - APGE
50%
Loosely correlated
+3.36%
More

NUVL and

Correlation & Price change

A.I.dvisor indicates that over the last year, NUVL has been loosely correlated with RVMD. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if NUVL jumps, then RVMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NUVL
1D Price
Change %
NUVL100%
+0.91%
RVMD - NUVL
62%
Loosely correlated
+2.73%
XENE - NUVL
61%
Loosely correlated
-0.60%
XNCR - NUVL
60%
Loosely correlated
-3.23%
IDYA - NUVL
59%
Loosely correlated
-0.19%
CGON - NUVL
58%
Loosely correlated
+1.47%
More